{
    "clinical_study": {
        "@rank": "26673", 
        "acronym": "GTN-01", 
        "arm_group": [
            {
                "arm_group_label": "MTX Single-dose chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Methotrexate (MTX) 0.4mg/(kg\u00b7d) intramuscularly (IM) on days 1-5; If \u03b2-hCG level can not drop to 1/10 of the origin level during the following 3 weeks, additional course is administered at 2-week intervals, after the first normal hCG value has been recorded."
            }, 
            {
                "arm_group_label": "MTX/Act-d Single-dose chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Act-d 0.6mg/m(2), IV, on day1,2; MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h); If \u03b2-hCG level can not drop to 1/10 of the origin level during the following 3 weeks, additional course is administered at 2-week intervals, after the first normal hCG value has been recorded."
            }, 
            {
                "arm_group_label": "MTX multiple courses chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "MTX 0.4mg/(kg\u00b7d) intramuscularly (IM) on days 1-5, 2-week intervals;\n1 cycle of chemotherapy should be given after the first normal hCG level."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will conduct a trial to determine whether methotrexate single-dose\n      treatment and methotrexate/Actinomycin-D single-dose treatment work well as multiple courses\n      of single agent chemotherapy in low-risk gestational trophoblastic neoplasia."
        }, 
        "brief_title": "Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gestational Trophoblastic Disease", 
            "Gestational Trophoblastic Neoplasia", 
            "Gestational Trophoblastic Tumor", 
            "Gestational Trophoblastic Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Trophoblastic Neoplasms", 
                "Gestational Trophoblastic Neoplasms", 
                "Hydatidiform Mole"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who FIGO Stage I, II, or III criteria for low-risk gestational trophoblastic\n             neoplasia (GTN);\n\n          -  WHO risk score 0-6;\n\n          -  Age\u226460 years; female, Chinese women;\n\n          -  Initial treatment is chemotherapy; patients who received prior low-dose methotrexate\n             for treatment of an ectopic pregnancy will be eligible for this study;\n\n          -  Performance status: Karnofsky score\u226560;\n\n          -  Laboratory tests: WBC\u22653.5\u00d710(9)/L, ANC\u22651.5\u00d710(9)/L, PLT\u226580\u00d710(9)/L, serum bilirubin\u2264\n             1.5 times the upper limit of normal, transaminase\u2264 1.5 times the upper limit of\n             normal, BUN, Cr\u2264 normal\n\n          -  Provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients with unconfirmed diagnosis of GTN;\n\n          -  Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic\n             tumor (ETT)\n\n          -  WHO risk score >6;\n\n          -  With severe or uncontrolled internal disease, unable to receive chemotherapy;\n\n          -  Concurrently participating in other clinical trials\n\n          -  Unable or unwilling to sign informed consents;\n\n          -  Unable or unwilling to abide by protocol."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823315", 
            "org_study_id": "2012-GYN/GTN-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MTX Single-dose chemotherapy", 
                    "MTX multiple courses chemotherapy"
                ], 
                "description": "MTX 0.4mg/(kg\u00b7d) intramuscularly (IM) on days 1-5", 
                "intervention_name": "MTX 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MTX/Act-d Single-dose chemotherapy", 
                "description": "MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h)", 
                "intervention_name": "MTX 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MTX/Act-d Single-dose chemotherapy", 
                "description": "Act-d 0.6mg/m(2), IV, on day1,2", 
                "intervention_name": "Act-d", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dactinomycin", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 29, 2013", 
        "location": [
            {
                "contact": {
                    "email": "weng.dh@gmail.com", 
                    "last_name": "Danhui Weng, MD", 
                    "phone": "+862783662681"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430030"
                    }, 
                    "name": "Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology"
                }, 
                "investigator": {
                    "last_name": "Ling Xi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "qljiangjie@yahoo.cn", 
                    "last_name": "Jie Jiang, MD, Ph D", 
                    "phone": "13791123139"
                }, 
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250012"
                    }, 
                    "name": "Qilu Hospital\uff0cShandong University"
                }, 
                "investigator": {
                    "last_name": "Jie Jiang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chenglili-@163.com", 
                    "last_name": "Lili Chen, MD", 
                    "phone": "13958138597"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310006"
                    }, 
                    "name": "Women's Hospital, School of Medicine, Zhejiang University"
                }, 
                "investigator": {
                    "last_name": "Lili Chen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Prospective, Randomized Trial of Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia", 
        "overall_contact": {
            "email": "weng.dh@gmail.com", 
            "last_name": "Danhui Weng, MD, PhD", 
            "phone": "+862783662681"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang University", 
            "last_name": "Xing Xie, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "It is difficult to estimate the exact cycles of chemotherapy\uff0cwe may calculate the rate of complete response and the rate of treatment failure at the preliminary end point of the trail.", 
                "measure": "Severity of adverse events as assessed by the WHO", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1-year"
            }, 
            {
                "description": "It is difficult to estimate the exact cycles of chemotherapy\uff0cwe may calculate the rate of complete response and the rate of treatment failure at the preliminary end point of the trail.", 
                "measure": "Complete response vs treatment failure", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823315"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Huazhong University of Science and Technology", 
            "investigator_full_name": "Ding Ma", 
            "investigator_title": "Director of the department of Obstetrics and Gynecology, Tongji Hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Resume menstruation", 
                "safety_issue": "No", 
                "time_frame": "at the time the first resume menstruation after treatment completed"
            }, 
            {
                "description": "to calculate the pregnancy rate in an actuarial manner using the Kaplan-Meier method at the end of the trail", 
                "measure": "The pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "to calculate the delivery rate in an actuarial manner using the Kaplan-Meier method at the end of the trail", 
                "measure": "the delivery rate with at least one live born baby", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "to observe the incidence of abnormal pregnancy i.e., stillbirths, neonatal deaths, miscarriages before 14 weeks, miscarriages after 14 weeks, terminations, ectopic pregnancy, molar pregnancy.", 
                "measure": "The incidence of abnormal pregnancy", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Huazhong University of Science and Technology", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Zhejiang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Huazhong University of Science and Technology", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ding Ma", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}